SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SomaLogic, Inc.

SomaLogic is fostering the discovery of effective and safer treatments for patients while empowering more accurate diagnosis, prevention, and treatment of disease through the next generation of proteomics.

SoftBank Capital

T. Rowe Price

Illumina

ARK Investment Management

Corvex

Counterpoint Global

Farallon Capital Management

Perceptive Advisors

Casdin Capital

Janus Henderson Investors

Ziff Capital Partners

Revelation Partners

Amgen

Boston Millennia Partners

Novartis

Redmile Group

Intermountain Ventures

Logos Capital

Millennium Management

SomaLogic

ICYMI ... Andra Krauze, MD, Physician Early Investigator and radiation oncologist at National Cancer Institute (NCI), presented how to effectively balance genomics, transcriptomics, and metabolomics, alongside proteomic platforms and clinical data, along with approaches for connecting proteomic data with the clinic. 

"Harnessing AI and proteomics for glioblastoma"

Catch up on the research here ➡️  https://lnkd.in/gnG4k5ex

#glioblastoma #biomarkerdiscovery #biomarkers 

How are academic, industry and government partners driving the precision neuroscience revolution, both as individual contributors and within the Global Neurodegeneration Proteomics Consortium?  

Now available! Chris Whelan, PhD, Carlos Cruchaga, PhD, and Keenan Walker, PhD, discuss their work measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.  
 
Access the on-demand webinar ➡️ https://bit.ly/3SdOT8r  
 
#Alzheimers # neuroscience #proteomics #biomarkers 

Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on using the NASH bundle of SomaSignal® Tests in a recently completed trial.

🎥 Watch today: Correlation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

#proteomics #biomarkers #drugdiscovery 

Catching up on research this week? Watch Ali Javaheri, MD, present findings from proteomics-based studies that identified ApoM as a mediator of risk in diabetes, heart failure, and chemotherapeutic cardiotoxicity, as well as the association between ApoM and heart failure outcomes, which has been validated in multiple cohorts using the SomaScan® Assay.

#proteomics #biomarkers #drugdiscovery 

Thank you to all the authors who have published discoveries they’ve made using the SomaScan® Assay. Each new study advances precision medicine worldwide – and inspires us to keep innovating.  
 
📖 Look through all their peer-reviewed research here: https://bit.ly/3RnkGSh 

Narrow your search by keyword. Or filter by date, and catch up on what’s new. 
 
#proteomics #biomarkers #drugdiscovery #drugdevelopment #aptamers 

	Dec '19	Dec '20	Dec '21	Dec '22
revenue	32.19M -	55.89M 73.64%	81.63M 46.05%	97.67M 19.65%
cost of revenue	49.72M -	22.61M 54.52%	33.46M 47.97%	43.36M 29.59%
gross profit	-17.53M -	33.27M 289.78%	48.16M 44.74%	54.30M 12.75%
selling and marketing expenses	100K -
general and administrative expenses	33.32M -
selling general and administrative expenses	33.42M -	36.88M 10.35%	77.97M 111.41%	156.62M 100.87%
research and development expenses	32.50M -	30.75M 5.39%	43.50M 41.46%	73.44M 68.85%
other expenses			681K -	1.95M 185.61%
cost and expenses	83.71M -	90.25M 7.81%	154.93M 71.68%	273.43M 76.48%
operating expenses	33.99M -	67.63M 98.98%	121.47M 79.60%	230.06M 89.40%
interest expense		18.34M -	1.32M 92.78%	-109.25M 8,351.59%
ebitda	-47.80M -	-31.30M 34.51%	-73.08M 133.46%	-167.71M 129.49%
operating income	-50.96M -	-34.36M 32.58%	-73.30M 113.37%	-175.76M 139.77%
depreciation and amortization	3.16M -	3.05M 3.29%	225K 92.63%	8.05M 3,477.33%
total other income expenses net	-6.04M -	-18.66M 208.67%	-14.24M 23.67%	65.89M 562.59%
income before tax	-57.00M -	-53.02M 6.99%	-87.55M 65.14%	-109.87M 25.50%
income tax expense		18.34M -	-1.25M 106.79%	-717K 42.41%
net income	-57.00M -	-71.35M 25.18%	-86.30M 20.95%	-109.16M 26.48%
weighted average shs out		181.16M -	137.16M 24.29%	183.99M 34.15%
weighted average shs out dil		181.16M -	137.16M 24.29%	183.99M 34.15%
eps	0 -	-0.39 Infinity%	-0.63 61.54%	-0.59 6.35%
epsdiluted	0 -	-0.39 Infinity%	-0.63 61.54%	-0.59 6.35%

COM:SOMALOGIC

SomaLogic Inc

Last Close

2.29

05/01 21:00

Market Cap

396.23M

Beta: -

Volume Today

33.91M

Avg: -

Preview